Ibcasertib

Ibcasertib
Clinical data
Other names	Chiauranib; CS-2164
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name N-(2-aminophenyl)-6-(7-methoxyquinolin-4-yl)oxynaphthalene-1-carboxamide;
CAS Number	1256349-48-0;
PubChem CID	49779393;
IUPHAR/BPS	10475;
DrugBank	DB16124;
ChemSpider	81367270;
UNII	F40IRN5981;
ChEMBL	ChEMBL5095033;
Chemical and physical data
Formula	C27H21N3O3
Molar mass	435.483 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COC1=CC2=NC=CC(=C2C=C1)OC3=CC4=C(C=C3)C(=CC=C4)C(=O)NC5=CC=CC=C5N;
	InChI InChI=1S/C27H21N3O3/c1-32-18-9-12-22-25(16-18)29-14-13-26(22)33-19-10-11-20-17(15-19)5-4-6-21(20)27(31)30-24-8-3-2-7-23(24)28/h2-16H,28H2,1H3,(H,30,31); Key:BRKWREZNORONDU-UHFFFAOYSA-N;

Ibcasertib is an investigational new drug that is being evaluated to treat small-cell lung cancer.^[1] Ibcasertib inhibits several angiogenesis-related kinases, including VEGFR1, VEGFR2, VEGFR3, PDGFRα, and c-Kit, as well as the mitosis-related kinase Aurora B and the chronic inflammation-related kinase CSF-1R.^[2]

References